Antipsychotic-Related Risks of Type 2 Diabetes Mellitus in Enrollees With Schizophrenia in the National Basic Public Health Service Program in Hunan Province, China

Bibliographic Data

ID15523142
AuthorsFeiyun Ouyang (Central South University), Jun He (0000-0002-5751-0867, Central South University), Xunjie Cheng (0000-0001-8766-0594, Central South University), Wei Zhou (0000-0002-0849-1524, Hunan University), Shirui Xiao (0000-0002-7770-3797, Central South University, corresponding author), Shuiyuan Xiao (0000-0002-2046-5564), Junqun Fang (Hunan Provincial Maternal and Child Health Hospital, corresponding author)
Year2022
Volume13
Pages754775-754775
Publication date2022-02-24
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueFrontiers in Psychiatry (JOURNAL)
Journal identifiersISSN: 1664-0640 • E-ISSN: 1664-0640
PublisherFrontiers Media (PUBLISHER • CH)
DOI10.3389/fpsyt.2022.754775
PMID35280179
OpenAlexW4213420922
LanguageEN
References cited47

Antipsychotics, especially clozapine, risperidone, chlorpromazine, and perphenazine, increased the T2DM risk among NBPHSP enrollees with schizophrenia. Mental health officers should accurately identify enrollees at a high risk of T2DM and take appropriate preventive measures to reduce the incidence of T2DM among patients with schizophrenia

Antipsychotic · Clozapine · Confidence interval · Diabetes mellitus · Hazard ratio · Olanzapine · Psychiatry · Risperidone · Schizophrenia (object-oriented programming · Type 2 Diabetes Mellitus · Diabetes Treatment and Management · Medicine · Parkinson's Disease Mechanisms and Treatments · Schizophrenia research and treatment · Endocrinology · Internal Medicine

Tools

Open DOIOpen Access